

# Treatment of Dry Eye Syndrome with Orally Administered CF101

## Data from a Phase 2 Clinical Trial

Isaac Avni, MD,<sup>1</sup> Hanna J. Garzoxi, MD,<sup>2</sup> Irina S. Barequet, MD,<sup>3</sup> Fanni Segev, MD,<sup>4</sup> David Varssano, MD,<sup>5</sup> Gil Sartani, MD,<sup>6</sup> Noa Chetrit, MD,<sup>1</sup> Erez Bakshi, MD,<sup>1</sup> David Zadok, MD,<sup>1</sup> Oren Tomkins, MD,<sup>2</sup> Gilad Litvin, MD,<sup>4</sup> Kenneth A. Jacobson, PhD,<sup>7</sup> Sari Fishman, PhD,<sup>8</sup> Ziv Harpaz, MSc,<sup>8</sup> Motti Farbstein, BSc,<sup>8</sup> Sara Bar Yehuda, PhD,<sup>8</sup> Michael H. Silverman, MD,<sup>8</sup> William D. Kerns, DVM,<sup>8</sup> David R. Bristol, PhD,<sup>8</sup> Ilan Cohn, PhD,<sup>8</sup> Pnina Fishman, PhD<sup>8</sup>

**Objective:** To explore the safety and efficacy of CF101, an A<sub>3</sub> adenosine receptor agonist, in patients with moderate to severe dry eye syndrome.

**Design:** Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-group study.

**Participants:** Sixty-eight patients completed the study, 35 patients in the placebo group and 33 patients in the CF101 group.

**Intervention:** Patients were treated orally with either 1 mg CF101 pills or matching vehicle-filled placebo pills, given twice daily for 12 weeks, followed by a 2-week posttreatment observation.

**Main Outcome Measures:** An improvement of more than 25% over baseline at week 12 in one of the following parameters: (1) tear break-up time (BUT); (2) superficial punctate keratitis assessed by fluorescein staining results; and (3) Schirmer tear test 1 results. Clinical laboratory safety tests, ophthalmic examinations, intraocular pressure (IOP) measurements, electrocardiographic evaluations, vital sign measurements, and monitoring of adverse events.

**Results:** A statistically significant increase in the proportion of patients who achieved more than 25% improvement in the corneal staining and in the clearance of corneal staining was noted between the CF101-treated group and the placebo group. Treatment with CF101 resulted in a statistically significant improvement in the mean change from baseline at week 12 of the corneal staining, BUT, and tear meniscus (TM) height in the CF101-treated group. CF101 was well tolerated and exhibited an excellent safety profile with no serious adverse events. A statistically significant decrease from baseline was observed in the IOP of the CF101-treated group in comparison with the placebo group.

**Conclusions:** CF101, given orally, induced a statistically significant improvement in the corneal staining and an improvement in the BUT and TM in patients with moderate to severe dry eye syndrome. The drug was very well tolerated. These data and the anti-inflammatory characteristic of CF101 support further study of the drug as a potential treatment for the signs and symptoms of dry eye syndrome.

**Financial Disclosure(s):** Proprietary or commercial disclosure may be found after the references. *Ophthalmology* 2010;117:1287–1293 © 2010 by the American Academy of Ophthalmology.

Dry eye syndrome is a multifactorial disease involving inflammation, autoimmunity, and damage to the surface of the eye. Dry eye syndrome has mainly 2 types: aqueous tear-deficient dry eye and evaporative dry eye. A combination of both also has been reported.<sup>1,2</sup> A more detailed classification system is based on: (1) etiopathogenicity, in which dry eye syndrome is divided into aqueous deficiency (Sjögren's or non-Sjögren's related) and evaporation (resulting from intrinsic or extrinsic causes); (2) mechanistic causes, including tear hyperosmolarity and tear film instability; and (3) severity of the disease with regard to visual symptoms, conjunctival injection, conjunctival staining results, corneal staining results, corneal or tear signs, lid or meibomian glands, tear film break-up time (tear film BUT), and Schirmer tear test results.<sup>3</sup>

Dry eye syndrome typically is an inflammatory condition

resulting from high levels of proinflammatory cytokines such as tumor necrosis factor  $\alpha$ , interleukin-1 $\beta$ , matrix metalloproteinase 9, and the chemokines macrophage inflammatory protein (MIP)-1 $\alpha$ , which were found in tear film and ocular surface epithelia.<sup>4–7</sup> In addition, examination of conjunctival biopsy specimens from patients with dry eye syndrome revealed massive lymphocyte infiltration and increased expression of human leukocyte antigen (HLA)-DR, HLA-DQ, intercellular adhesion molecule 1 (ICAM)-1, cluster of differentiation (CD)-40, CD40 ligand, and apoptotic marker APO2.<sup>7,8–10</sup>

The current most widely used treatment for dry eye is artificial tears, which may relieve eye irritation, blurred vision symptoms and improve tear film BUT and fluorescein staining (FS). Further management may emphasize

either immunosuppressive or anti-inflammatory drugs such as corticosteroids, tetracyclines, and cyclosporine A, or agents that work via the secretagogue route, aiming at the promotion of tear production. Such agents include mucin secretion stimulants, diadenosine polyphosphatases, and other purinergic P2Y<sub>2</sub> receptor agonists.<sup>1,11–14</sup> Current treatments are directed toward symptomatic therapeutic approaches. Thus, management focused on the underlying pathogenic pathways may offer better outcomes.

The adenosine receptor agonist (A<sub>3</sub>AR) is a Gi protein-coupled cell surface receptor that belongs to the adenosine receptor family that includes also the A<sub>1</sub>, A<sub>2A</sub>, and A<sub>2B</sub> adenosine receptors.<sup>15</sup> CF101, generically known as IB-MECA (generic name of CF101), is an A<sub>3</sub>AR agonist shown in preclinical and clinical studies to mediate a marked anti-inflammatory effect. The binding of CF101 to the A<sub>3</sub>AR initiates downstream signal transduction pathways, which entail downregulation of PKB/Akt (protein kinases B/Akt) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), resulting in the inhibition of tumor necrosis factor α and MIP-1α. In addition, CF101 inhibits the proliferation of autoreactive T cells and the production of chemokines.<sup>16–19</sup> The therapeutic potential for CF101 as an anti-inflammatory agent was established in experimental animal models of arthritis, inflammatory bowel disease, osteoarthritis, and septic peritonitis, in which CF101 treatment suppressed inflammatory manifestations and prevented tissue damage.<sup>16–22</sup>

Human phase 1 clinical studies, including single- and repeated-dose trials in healthy volunteers, established CF101 as apparently safe and well tolerated. Pharmacokinetic parameters, which were linearly proportional to dose, demonstrated that a maximal plasma concentration of CF101 was achieved at 1 to 2 hours, with an elimination half-life of approximately 9 hours.<sup>23</sup> In a phase 2a clinical study in patients with rheumatoid arthritis, CF101 administered twice daily orally for 12 weeks resulted in an improvement of disease signs and symptoms and seemed to act as a disease-modifying antirheumatic drug.<sup>24</sup> In the rheumatoid arthritis population, CF101 was safe and very well tolerated.

The marked anti-inflammatory effect of CF101, together with its good safety profile and oral bioavailability, led us to explore its effect on moderate to severe dry eye syndrome. Based on prior experience in rheumatoid arthritis trials, a CF101 dose of 1 mg twice daily was selected.

## Patients and Methods

### Study Design

This report describes a randomized, multicenter, doubled-masked, placebo-controlled, parallel-group phase 2 clinical study that examined the safety and efficacy of daily CF101 administered orally in patients with moderate to severe dry eye syndrome. The study was composed of a screening period of up to 4 weeks, which included a 2-week run-in period, followed by a 12-week treatment period and a 2-week follow-up. The study was conducted in 5 investigative sites in Israel, in compliance with good clinical practices, investigational site institutional review board regulations, informed consent regulations, and the Declaration of Helsinki.

### Patients

Patients were required to be 18 years of age or older with a diagnosis of moderate to severe dry eye syndrome as defined by: (1) at least one ocular symptom from among photophobia, blurred vision, foreign body sensation, soreness or pain, itching, burning, or dryness scored at 2 or more (where 0 = none and 4 = very severe or interferes with normal activities); (2) Schirmer tear test 1 (ST1) results without anesthesia and less than 7 mm/5 minutes in either eye; and (3) positive fluorescein staining (FS) results, defined as a corneal punctate fluorescein staining score of 1 or more in either eye (where 0 = none and 3 = severe). Patients were not allowed to use any topical ocular treatments except unpreserved artificial tears. In addition, periocular cosmetic application was not allowed for the duration of the study.

Patients were excluded from the study if they had a history of Sjögren's syndrome with significant systemic nonexocrine gland involvement, Stevens-Johnson syndrome, postburn ocular injury, or chronic ocular disease other than dry eye syndrome requiring topical treatment. Also excluded were patients being administered topical cyclosporine eye drops or systemic cyclosporine within 3 months before the screening visit; disease-modifying drugs, including methotrexate and biological agents, the dose of which had been changed within 3 months before the screening visit or was expected to change during the trial; oral corticosteroids consisting of 10 mg prednisone or more, or equivalent, per day; or topical steroids within 2 weeks before the screening visit and for the duration of the study. Additional exclusion criteria included ocular herpes simplex virus infection; use of contact lenses concomitantly or within 3 months; persistent intraocular inflammation or infection; active blepharitis of greater than mild degree; recent surgical occlusion of the lacrimal puncta; subepithelial corneal scarring; anesthetic or neurotrophic corneas; presence or history of uncontrolled asthma; any evidence of clinically significant heart disease; pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the investigator; participation in another investigational drug or vaccine trial concurrently or within 30 days; or other conditions that would confound the study evaluations or endanger the safety of the patient.

### Study Protocol

This was a phase 2, randomized, double-masked, placebo-controlled, parallel-group study. Patients were assigned randomly to treatment with either 1 mg CF101 (methyl 1-[N<sup>6</sup>-(3-iodobenzyl)-adenin-9-yl]-β-D-ribofuronamide) pills or matching vehicle-filled placebo pills, given twice daily for 12 weeks. Patients also were provided with individually packaged preservative-free artificial tears (Refresh Lubricant Eye Drops, Allergan, Inc, Irvine, CA) that served as adjuvant treatment to be used up to 8 times daily for the duration of the trial.

Patients qualified for the trial after a screening period of up to 4 weeks, which included a 2-week run-in period during which time they were instructed to discontinue use of all topical ophthalmic medications except for Refresh eye drops. Patients who completed the run-in period successfully were randomized to their assigned medication. The patients returned for clinical assessments and a new supply of study medication at weeks 2, 4, 8, and 12, and at week 14 for a final follow-up assessment after 2 weeks without treatment.

### Outcome Measures

**Efficacy.** The primary efficacy end point was the proportion of successes, where success was defined to be an improvement of 25% or more over baseline at week 12 in tear film BUT, or an

improvement of 25% or more over baseline at week 12 in superficial punctate keratitis as assessed by either FS or ST1 results. The assessment of superficial punctate erosions using FS was the sum of scores from nasal, temporal, pupil, and inferior segments (graded on a scale from 0 = none to 3 = severe). The primary efficacy analysis was performed for 1 eye (target eye), defined as the eye with the worse Schirmer value at baseline. If both eyes had the same ST1 value at baseline, the worse eye was considered the eye with the worse superficial punctate keratitis value at baseline. If both of these assessments again were the same for both eyes, then the left eye was the target eye.

The primary end point was the proportion of successes (% of patients), where success was defined to be an improvement of more than 25% over baseline at week 12 in tear film BUT and in superficial punctate keratitis as assessed by FS or ST1 results. The secondary end points were mean change from baseline at week 12 for tear film BUT, superficial punctate keratitis as assessed by FS and ST1 results for the target eye, and the same analyses (proportion of successes and mean change from baseline) for the nontarget eye, as well as average of the 2 eyes. Other secondary analyses were performed for change from baseline at week 12 in tear meniscus (TM) for the target eye and dry eye symptom score (DESS).<sup>25</sup> The DESS is a questionnaire consisting of 12 questions designed to assess the symptoms of ocular irritation covering 3 areas: ocular symptoms, environmental triggers, and vision-related function.

**Safety.** The safety of CF101 was assessed by recording the nature, severity, and duration of all adverse events and their relationship to the study medication, as judged by the investigator. Additional safety end points included clinical laboratory safety testing (clinical chemistry, hematologic analysis, and urinalysis), physical examinations, slit-lamp and ophthalmic examinations, IOP measurements, electrocardiographic evaluations, and vital sign measurements. Safety was evaluated at all visits, starting from baseline throughout the study and on week 14.

## Statistical Considerations

The between-treatment comparison with the success rate was performed using the Fisher exact test. The analyses of the secondary variables, other than change from baseline in TM, were performed using analysis of covariance with the baseline assessment of the variable as the covariate. Change from baseline in TM was performed using the Wilcoxon rank-sum test. All tests were performed at the 0.05 significance level. Safety end points were summarized by treatment group using descriptive statistics.

## Results

### Participant Flow and Follow-up

A total of 101 patients were screened for the study; 21 failed the run-in period and dropped out before treatment. Eighty patients

Table 1. Patient Disposition

	Placebo	CF101
Enrolled	38	42
Completed	35 (92%)	33 (79%)
Discontinued		
Withdrawal of consent by the patient	0	4 (9%)
Occurrence of adverse events	0	2 (5%)
Noncompliance	3 (8%)	2 (5%)
The patient condition required a change in a concomitant medication	0	1 (2%)

Table 2. Patient Demographics

	Placebo	CF101
Age (yrs)	61.73±1.94	52.56±2.19
Gender		
Male	10 (27%)	17 (44%)
Female	27 (73%)	22 (56%)

entered the study, 38 in the placebo group and 42 in the CF101-treated group, and 85% (68/80) completed the study (Table 1). The first patient was enrolled in November 2008, and the last patient completed the 12-week treatment and 2-week follow up in May 2009. Patient disposition is presented in Table 1.

### Patient Demographics and Characteristics at Baseline

All the patients were white. Most patients were women (49/76 [65%]). There was no statistically significant difference in patient age between the CF101-treated and the placebo-treated groups (Table 2). At baseline, no statistical differences in FS, tear film BUT, TM, and ST1 results were recorded between the placebo and the CF101-treated groups (Table 3).

### Efficacy Analysis

In the CF101-treated group, 84.6% of the patients achieved more than 25% improvement in the corneal staining (success as defined by the primary efficacy end point of the trial) in comparison with 52.2% in the placebo group ( $P = 0.06$  on week 12). Discontinuation of the treatment led to a reduction in the proportion of successes in the CF101-treated group, suggesting that the improvement in the corneal staining was attributed to CF101 (Fig 1).

Furthermore, analysis of mean change from baseline of the corneal staining (measured by FS) revealed a progressive improvement in the CF101-treated group versus placebo throughout the treatment duration, with a statistically significant difference on week 12 ( $P = 0.004$ ; Fig 2). Additionally, there was a statistically significant difference in the clearing of corneal staining between the CF101 and the placebo-treated groups in the nasal, temporal, pupil, and inferior parts of the cornea, indicating consistency of effect across the ocular surface (Fig 3).

An improvement in the mean change from baseline of the tear film BUT was observed in the CF101-treated and placebo groups ( $P = 0.0025$  and  $P = 0.014$ , respectively); however, a higher rate of improvement was noted in the CF101-treated group (Fig 4). Analysis of the TM data revealed a statistically significant difference in the mean change from baseline at week 12 between the CF101-treated and the placebo groups ( $P = 0.02$ ; Fig 5). No effect of the drug on ST1 results or DESS was observed.

Table 3. Baseline Dry Eye Syndrome Parameter Values

	Placebo	CF101
FS (score)	3.16±0.33	2.8±0.42
BUT (sec)	4.34±0.5	5.06±0.45
ST1 (mm)	2.97±0.33	3.0±0.33
IOP (mmHg)	14.23±0.44	13.31±0.43

BUT = tear break-up time; FS = fluorescein staining; IOP = intraocular pressure; ST1 = Schirmer tear test 1.




Figure 1. Graph showing the percent of patients who achieved more than 25% improvement from baseline in the corneal staining score. \*Statistically significant difference between CF101-treated group and placebo ( $P = 0.006$ ). Placebo group,  $n = 37$ ; CF101 group,  $n = 39$ .

### Safety Analysis

No serious adverse events were noted throughout the study. Adverse events resulting in discontinuation of the study were observed in 2 patients: myalgias and recurrent corneal erosion. The frequency of adverse events was comparable in both treated groups (Table 4). The most frequently reported adverse events included constipation, headache, palpitations, itching, abdominal pain, arthralgia, myalgia, fatigue, and dry mouth (Table 5).

Orally administered CF101 1 mg twice daily was well tolerated and exhibited an excellent safety profile. No clinically significant changes in vital signs, electrocardiograms, blood chemistry results, and hematology values were observed. Although the trial was not designed to assess the effects of treatment on IOP, it was noted that, at week 12, the CF101-treated group showed a 1.1-mmHg decrease from baseline, which was statistically significant at a  $P = 0.048$  level when compared with that of placebo.

### Discussion

This study presents data showing that CF101, administered orally, induced a statistically significant short-term improvement in the corneal staining in patients with moderate




Figure 2. Graph showing the mean change from baseline in the corneal staining. \*Statistically significant difference between CF101-treated group and placebo ( $P = 0.004$ ). Placebo group,  $n = 37$ ; CF101 group,  $n = 39$ .




Figure 3. Bar graph showing the percentage of patients that achieved clearing of fluorescein staining (FS) in the various regions of the cornea at week 12.

to severe dry eye syndrome. An improvement in the tear film BUT and TM also was observed. CF101 was well tolerated with no severe adverse events and a safety profile consistent with that reported in previous trials.<sup>23</sup>

In patients treated with CF101, the corneal staining scores were significantly lower at end point compared with placebo and decreased gradually over the study period. Notably, 2 weeks after cessation of therapy, the beneficial effects of CF101 with respect to corneal staining were diminished. The corneal staining reflects defects on the ocular surface that led to infection, inflammation, scarring, and visual acuity,<sup>26,27</sup> thus suggesting that a longer treatment period may impact on additional manifestations of dry eye syndrome and could improve DESS, as well. The time-dependent improvement of this objective measure of cor-




Figure 4. Bar graph showing the mean change from baseline at week 12 in the tear film break-up time (BUT). \*Statistically significant on week 12 versus baseline. Placebo group,  $n = 37$  ( $P = 0.014$ ); CF101 group,  $n = 39$  ( $P = 0.0025$ ).




Figure 5. Bar graph showing the mean change from baseline at week 12 in the tear meniscus (TM) height. \*Statistically significant on week 12 versus baseline. Placebo group, n = 37; CF101 group, n = 39 ( $P = 0.014$ ).

neal integrity, coupled with the rebound of the disease within 2 weeks after the discontinuation of treatment, strongly suggest that CF101 is exerting an anti-inflammatory effect at the ocular surface.

Furthermore, FS clearance was observed consistently across most portions of the cornea, being statistically significant in favor of CF101 in all but the temporal sector. This result seems to have both precedence and clinical relevance, because the FS clearance parameter recently was incorporated as an efficacy end point for a phase 3 dry eye syndrome trial of Diquafosol tetrasodium (Inspire Pharmaceuticals, Inc, Durham, NC), which targets the Gq protein-coupled P2Y<sub>2</sub> receptor, a member of the adenosine triphosphate (ATP) receptor family. Diquafosol promotes nonglandular secretion of fluid (water transport via chloride channel activation), mucin secretion, and possibly lipid production in the meibomian glands.<sup>14,28</sup> Because common mechanistic pathways are shared between the different purine receptor family members, it may be that, in addition to the anti-inflammatory effect mediated via the A<sub>3</sub>AR, CF101 also may induce its beneficial effect via fluid and mucin secretion. Indeed, previous studies showed that the A<sub>3</sub>AR is the only adenosine receptor that

Table 4. Treatment-Related Adverse Events: Safety Population

	Placebo (n = 38)	CF101 (n = 43)
Any adverse event	26 (68%)	25 (58%)
Serious adverse events	0	0
Adverse events resulting in discontinuation	0	2 (8%)
Death	0	0

Table 5. Most Frequently Reported Adverse Events

	Placebo (n = 38)	CF101 (n = 43)
Constipation	2 (5%)	3 (7%)
Headache	4 (10%)	3 (7%)
Palpitations	0	3 (7%)
Itching	1 (3%)	3 (7%)
Abdominal pain	0	2 (5%)
Arthralgia	1 (3%)	2 (5%)
Myalgia	0	2 (5%)
Fatigue	0	2 (5%)
Dry mouth	1 (3%)	0

activates chloride channels in pigmented and nonpigmented epithelial cells. This was shown both in vitro and in vivo using A<sub>3</sub>AR agonists such as IB-MECA and Cl-IB-MECA.<sup>29–31</sup>

The core mechanisms of dry eye are driven by tear hyperosmolarity and tear film instability. Tear hyperosmolarity causes damage to the surface epithelium by activating a cascade of inflammatory events at the ocular surface and a release of inflammatory mediators into the tears. Epithelial damage involves cell death by apoptosis, a loss of goblet cells, and disturbance of mucin expression, leading to tear film instability.<sup>32,33</sup> The capability of CF101 to act as an anti-inflammatory agent, together with its effects on ion transport, may suggest its beneficial effect in dry eye syndrome.

The ST1 was conducted in the present study without anesthesia and is known to be cumbersome, rough, primitive, and inaccurate, possibly explaining the negative outcome. Similar data were found in patients with moderate to severe dry eye syndrome who were treated with Restasis. However, significant improvement in ST1 results conducted with anesthesia were observed in the Restasis trial after 4 months,<sup>34</sup> suggesting that the design for the ST1 analysis in the Restasis study needs to be adopted for future studies with CF101.

In addition, this study demonstrated that CF101 treatment induced a statistically significant reduction in the IOP. During the last decade, Yang et al have published that A<sub>3</sub>AR agonists activate Cl channels in the nonpigmented ciliary epithelial cells, leading to an increase of the water inflow to the anterior chamber, thereby elevating the IOP both in vitro and in vivo.<sup>30</sup> A point to note is that under these lab conditions, the animals were treated once, and IOP measurement was examined immediately after the treatment. In our clinical study, the patients were treated chronically, and the drug reached steady state plasma levels to induce either direct or indirect effects.

The concept of treating dry eye syndrome with an oral drug is based on much better patient compliance than that associated with a topical treatment. The use of CF101 for the treatment of dry eye syndrome was enabled based on its apparent safety profile and continued anti-inflammatory effect for a long period, up to 18 month (Can-Fite Internal Report, 2008). Long-term studies to treat dry eye syndrome patients with CF101 are underway to establish this drug as an efficacious treatment for this condition. The CF101 anti-inflammatory mechanism of action, which may affect the disease pathogenesis, can be suggested as a novel approach to treat both the cause and the symptoms of the disease. This

approach distinguishes CF101 from the current standard care of treatment today. Thus, in future clinical development, CF101 will be administered as a monotherapy and most probably will be compared with placebo.

To conclude, the clinical results from this proof-of-concept study support further evaluation of CF101 as a potential treatment for the signs and symptoms of dry eye disease. The safety profile of CF101, as initially established in this and other trials,<sup>23</sup> supports the long-term investigation that is necessitated by the chronic, inflammatory nature of dry eye disease.

## References

1. Latkany R. Dry eyes: etiology and management. *Curr Opin Ophthalmol* 2008;19:287–91.
2. Fox RI, Stern M, Michelson P. Update in Sjögren's syndrome. *Curr Opin Rheumatol* 2000;12:391–8.
3. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye Workshop (2007). *Ocul Surf* 2007;5:75–92.
4. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. *Invest Ophthalmol Vis Sci* 2004;44:293–301.
5. Acera A, Rocha G, Vecino E, et al. Inflammatory markers in the tears of patients with ocular surface disease. *Ophthalmic Res* 2008;40:315–21.
6. Pflugfelder SC, Farley W, Luo L, et al. Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye. *Am J Pathol* 2005;166:61–71.
7. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. *Invest Ophthalmol Vis Sci* 2007;48:2561–9.
8. Tsubota K, Fukagawa K, Fujihara T, et al. Regulation of human leukocyte antigen expression in human conjunctival epithelium. *Invest Ophthalmol Vis Sci* 1999;40:28–34.
9. Pisella PJ, Brignole F, Debbasch C, et al. Flow cytometric analysis of conjunctival epithelium in ocular rosacea and keratoconjunctivitis sicca. *Ophthalmology* 2000;107:1841–9.
10. de Paiva CS, Pflugfelder SC. Rationale for anti-inflammatory therapy in dry eye syndrome. *Arq Bras Oftalmol* 2008; 71(suppl):89–95.
11. Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J. Therapeutic targets in dry eye syndrome. *Drug News Perspect* 2008;21:166–76.
12. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. *Surv Ophthalmol* 2009;54:321–38.
13. Pintor J, Peral A, Hoyle CH, et al. Effects of diadenosine polyphosphates on tear secretion in New Zealand white rabbits. *J Pharmacol Exp Ther* 2002;300:291–7.
14. Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. *Cornea* 2004;23:784–92.
15. Stiles GL. Adenosine receptors and beyond: molecular mechanisms of physiological regulation. *Clin Res* 1990;38:10–8.
16. Baharav E, Bar-Yehuda S, Madi L, et al. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. *J Rheumatol* 2005;32:469–76.
17. Fishman P, Bar-Yehuda S, Madi L, et al. The PI3K–NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis [article online]. *Arthritis Res Ther* 2006;8:R33. Available at: <http://arthritis-research.com/content/8/1/R33>. Accessed November 8, 2009.
18. Rath-Wolfson L, Bar Yehuda S, Madi L, et al. IB-MECA, an A3 adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. *Clin Exp Rheumatol* 2006;24: 400–6.
19. Bar-Yehuda S, Silverman MH, Kerns WD, et al. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. *Expert Opin Investig Drugs* 2007;16:1601–13.
20. Mabley J, Soriano F, Pacher P, et al. The adenosine A3 receptor agonist, N6-(3-iodobenzyl)-adenosine-5'-N-methyluronamide, is protective in two murine models of colitis. *Eur J Pharmacol* 2003;466:323–9.
21. Bar-Yehuda S, Rath-Wolfson L, Del Valle L, et al. Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. *Arthritis Rheum* 2009;60:3061–71.
22. Lee HT, Kim M, Joo JD, et al. A3 adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. *Am J Physiol Regul Integr Comp Physiol* 2006;291:R959–69.
23. van Troostenburg AR, Clark EV, Carey WD, et al. Tolerability, pharmacokinetics, and concentration-dependent hemodynamic effects of oral CF101, an A3 adenosine receptor agonist, in healthy young men. *Int J Clin Pharmacol Ther* 2004; 42:534–42.
24. Silverman MH, Strand V, Markovits D, et al. Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. *J Rheumatol* 2008;35:41–8.
25. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. *Arch Ophthalmol* 2000;118:615–21.
26. Cohen IJ. Use of fluorescein in eye injuries. *J Occup Med* 1963;5:540–1.
27. Holland MC. Fluorescein staining of the cornea. *JAMA* 1964; 188:81.
28. Kellerman D, Rossi Mospan A, Engels J, et al. Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. *Pulm Pharmacol Ther* 2008;21:600–7.
29. Carré DA, Mitchell CH, Peterson-Yantorno K, et al. Similarity of A(3)-adenosine and swelling-activated Cl(–) channels in nonpigmented ciliary epithelial cells. *Am J Physiol Cell Physiol* 2000;279:C440–51.
30. Yang H, Avila MY, Peterson-Yantorno K, et al. The cross-species A3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. *Curr Eye Res* 2005;30:747–54.
31. Do CW, Civan MM. Swelling-activated chloride channels in aqueous humour formation: on the one side and the other. *Acta Physiol (Oxf)* 2006;187:345–52.
32. Liu H, Begley CG, Chen M, et al. A link between tear instability and hyperosmolarity in dry eye. *Invest Ophthalmol Vis Sci* 2009;50:3671–9.
33. Yeo AC, Carkeet A, Carney LG, Yap MK. Relationship between goblet cell density and tear function tests. *Ophthalmic Physiol Opt* 2003;23:87–94.
34. Sall K, Stevenson OD, Mundorf TK, Reis BL, CsA Phase 3 Study Group. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. *Ophthalmology* 2000;107: 631–9.

## Footnotes and Financial Disclosures

---

Originally received: August 17, 2009.

Final revision: October 16, 2009.

Accepted: November 13, 2009.

Available online: March 20, 2010.

Manuscript no. 2009-1113.

<sup>1</sup> Assaf Harofe Medical Center, Zeriffin, Beer Yaakov, Israel.

<sup>2</sup> Bnei Zion Medical Center, Haifa, Israel.

<sup>3</sup> Goldschleger Eye Institute, Sheba Medical Center, Sackler Faculty of Medicine, Tel Hashomer, Israel.

<sup>4</sup> Meir Medical Center, Kfar-Saba, Israel.

<sup>5</sup> Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.

<sup>6</sup> Haemek Medical Center, Afula, Israel.

<sup>7</sup> National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland.

<sup>8</sup> Can-Fite BioPharma Ltd, Petach Tikva, Israel.

Financial Disclosure(s):

The author(s) have made the following disclosure(s):

Isaac Avni - Equity Owner - Can-Fite BioPharma

Sari Fishman - Employee - Can-Fite BioPharma

Zivit Harpaz - Employee - Can-Fite BioPharma

Motti Farbstein - Employee - Can-Fite BioPharma

Sara Bar Yehuda - Employee - Can-Fite BioPharma

Michael H. Silverman - Employee - Can-Fite BioPharma

William D. Kerns - Employee - Can-Fite BioPharma

Ilan Cohn - Employee - Can-Fite BioPharma

Pnina Fishman - Employee - Can-Fite BioPharma

Sponsored by Can-Fite BioPharma Ltd, Petach Tikva, Israel. Supported in part by the Intramural Research Program of the National Institute of Diabetes & Digestive & Kidney Diseases, National Institutes of Health, Bethesda, Maryland.

Correspondence:

Pnina Fishman, PhD, Can-Fite BioPharma Ltd, 10 Bareket Street, Petach Tikva 49170, Israel. E-mail: [pnina@canfite.co.il](mailto:pnina@canfite.co.il).